Blockade of Sodium Glucose Cotransporter 2 Suppresses High Glucose-induced Angiotensinogen Augmentation in Renal Proximal Tubular Cells.
Renal proximal tubular angiotensinogen (AGT) is increased by hyperglycemia (HG) in diabetes mellitus, which augments intrarenal angiotensin II formation contributing to the development of hypertension and kidney injury. Sodium glucose co-transporter 2 (SGLT2) is abundantly expressed in proximal tubular cells (PTC). This study investigated the effects of canagliflozin (CANA), an SGLT2 inhibitor, on HG-induced AGT elevation in cultured PTC. Mouse PTC were treated with 5-25 mM glucose. 0-10 µM CANA was applied one hour before glucose treatment. 10 mM glucose increased AGT mRNA and protein levels at 12 hours (3.06 ± 0.48-fold in protein), and 1 and 10µM CANA as well as SGLT2 shRNA attenuated the AGT augmentation. CANA did not suppress the elevated AGT levels induced by 25 mM glucose. Increased AGT expression induced by treatment with pyruvate, a glucose metabolite that does not require SGLT2 for uptake, was not attenuated by CANA. In HG-treated PTC, intracellular ROS levels were elevated compared to baseline (4.24 ± 0.23-fold) and these were also inhibited by CANA. Furthermore, Tempol, an antioxidant, attenuated AGT upregulation in HG-treated PTC. HG-induced AGT upregulation was not inhibited by an angiotensin II receptor antagonist, indicating that HG stimulates AGT expression in an angiotensin II-independent manner. These results indicate that enhanced glucose entry via SGLT2 into PTC elevates intracellular ROS generation by stimulation of glycolysis and consequent AGT augmentation. SGLT2 blockade limits HG-induced AGT stimulation, thus reducing the development of kidney injury in diabetes mellitus.